Renal replacement therapy in ADPKD patients: A 25-year survey based on the Catalan registry

BMC Nephrology

Volumn 14, Issue 1, 2013, Pages

  Martínez, Víctor ^a   Comas, Jordi ^b   Arcos, Emma ^b   Díaz, Joan Manel ^c   Muray, Salomé ^a   Cabezuelo, Juan ^a   Ballarín, José ^b   Ars, Elisabet ^c   Torra, Roser ^c  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b Catalan Transplant Organization   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

ADPKD; Autosomal dominant polycystic kidney disease; Co morbidities; Renal replacement therapy; Survival

Indexed keywords

ADULT; ARTHROPATHY; ARTICLE; CARDIOVASCULAR RISK; CHRONIC DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HEALTH CARE SURVEY; HEART LEFT VENTRICLE HYPERTROPHY; HEMATURIA; HEPATITIS C VIRUS; HUMAN; HYPERTENSION; HYPERURICEMIA; KIDNEY GRAFT; KIDNEY POLYCYSTIC DISEASE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; PREVALENCE; RENAL REPLACEMENT THERAPY; RESPIRATORY TRACT DISEASE; SPAIN; SURVIVAL RATE; URINE OSMOLALITY;

AGE DISTRIBUTION; COMORBIDITY; FEMALE; HEALTH CARE SURVEYS; HUMANS; HYPERTENSION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PREVALENCE; REGISTRIES; RENAL REPLACEMENT THERAPY; RISK FACTORS; SEX DISTRIBUTION; SPAIN; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84883448478     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-14-186     Document Type: Article

References (51)

1. 2008 Homer W. Smith Award: insights into the pathogenesis of polycystic kidney disease from gene discovery. Harris PC, J Am Soc Nephrol 2009 20 1188 1198 10.1681/ASN.2009010014 19423684
2. Linkage, clinical features, and prognosis of autosomal dominant polycystic kidney disease types 1 and 2. Torra R, Badenas C, Darnell A, Nicolau C, Volpini V, Revert L, et al. J Am Soc Nephrol 1996 7 2142 2151 8915974 (Pubitemid 27468243)
3. Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Hateboer N, Dijk MA, Bogdanova N, Coto E, Saggar-Malik AK, San Millan JL, et al. Lancet 1999 353 103 107 10.1016/S0140-6736(98)03495-3 10023895 (Pubitemid 29088079)
4. US Renal Data System 2010 Annual Data Report. Collins AJ, Foley RN, Herzog C, Chavers B, Gilbertson D, Ishani A, et al. Am J Kidney Dis 2011 57 8, e1 A8,526
5. Catalan Transplant Organisation HD, Generalitat de Catalunya Barcelona: Generalitat de Catalunya, Servei Catala de la Salut Catalan Renal Registry. 2009 Statistical report. 20-11-2011. Ref Type: Catalog
6. Earlier diagnosis of autosomal dominant polycystic kidney disease: importance of family history and implications for cardiovascular and renal complications. Taylor M, Johnson AM, Tison M, Fain P, Schrier RW, Am J Kidney Dis 2005 46 415 423 10.1053/j.ajkd.2005.05.029 16129202 (Pubitemid 41208176)
7. Autosomal dominant polycystic kidney disease: comprehensive mutation analysis of PKD1 and PKD2 in 700 unrelated patients. Audrezet MP, Cornec-Le GE, Chen JM, Redon S, Quere I, Creff J, et al. Hum Mutat 2012 33 1239 1250 10.1002/humu.22103 22508176
8. Type of PKD1 Mutation Influences Renal Outcome in ADPKD. Cornec-Le GE, Audrezet MP, Chen JM, Hourmant M, Morin MP, Perrichot R, et al. J Am Soc Nephrol 2013 24 1006 1013 10.1681/ASN.2012070650 23431072
9. Hypertension in autosomal dominant polycystic kidney disease. Chapman AB, Stepniakowski K, Rahbari-Oskoui F, Adv Chronic Kidney Dis 2010 17 153 163 10.1053/j.ackd.2010.01.001 20219618
10. Renal disease progression in autosomal dominant polycystic kidney disease. Higashihara E, Horie S, Muto S, Mochizuki T, Nishio S, Nutahara K, Clin Exp Nephrol 2012 16 622 628 10.1007/s10157-012-0611-9 22526483
11. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. Longenecker JC, Coresh J, Powe NR, Levey AS, Fink NE, Martin A, et al. J Am Soc Nephrol 2002 13 1918 1927 10.1097/01.ASN.0000019641.41496.1E 12089389 (Pubitemid 34700618)
12. Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland. Haroun MK, Jaar BG, Hoffman SC, Comstock GW, Klag MJ, Coresh J, J Am Soc Nephrol 2003 14 2934 2941 10.1097/01.ASN.0000095249.99803.85 14569104 (Pubitemid 37305656)
13. Health care utilization among patients with chronic kidney disease. Khan SS, Kazmi WH, Abichandani R, Tighiouart H, Pereira BJ, Kausz AT, Kidney Int 2002 62 229 236 10.1046/j.1523-1755.2002.00432.x 12081582 (Pubitemid 34754066)
14. Blood pressure and survival in long-term hemodialysis patients with and without polycystic kidney disease. Molnar MZ, Lukowsky LR, Streja E, Dukkipati R, Jing J, Nissenson AR, et al. J Hypertens 2010 28 2475 2484 20720499
15. Variation in age at ESRD in autosomal dominant polycystic kidney disease. Reed BY, McFann K, Reza BM, Nobkhthaghighi N, Masoumi A, Johnson AM, et al. Am J Kidney Dis 2008 51 173 183 10.1053/j.ajkd.2007.10.037 18215695
16. Improved Prognosis in Patients with Autosomal Dominant Polycystic Kidney Disease in Denmark. Orskov B, Romming S, Feldt-Rasmussen B, Strandgaard S, V, Clin J Am Soc Nephrol 2010 5 2034 2039 10.2215/CJN.01460210 20671227
17. Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease. Schrier RW, McFann KK, Johnson AM, Kidney Int 2003 63 678 685 10.1046/j.1523-1755.2003.00776.x 12631134 (Pubitemid 36126815)
18. Use of antihypertensive medications and mortality of patients with autosomal dominant polycystic kidney disease: a population-based study. Patch C, Charlton J, Roderick PJ, Gulliford MC, Am J Kidney Dis 2011 57 856 862 10.1053/j.ajkd.2011.01.023 21458899
19. End-stage renal failure appears earlier in men than in women with polycystic kidney disease. Stewart JH, Am J Kidney Dis 1994 24 181 183 8048422 (Pubitemid 24249055)
20. Outcomes of renal transplantation in patients with autosomal dominant polycystic kidney disease: a nationwide longitudinal study. Jacquet A, Pallet N, Kessler M, Hourmant M, Garrigue V, Rostaing L, et al. Transpl Int 2011 24 582 587 10.1111/j.1432-2277.2011.01237.x 21352383
21. The epidemic of aging in renal replacement therapy: an update on elderly patients and their outcomes. Jager KJ, van Dijk PC, Dekker FW, Stengel B, Simpson K, Briggs JD, Clin Nephrol 2003 60 352 360 10.5414/CNP60352 14640241 (Pubitemid 37407693)
22. Is gender a determinant for evolution of renal failure? A study in autosomal dominant polycystic kidney disease. Gretz N, Zeier M, Geberth S, Strauch M, Ritz E, Am J Kidney Dis 1989 14 178 183 2672797 (Pubitemid 19241463)
23. Trends in incidence of end-stage renal disease in Japan, 1983-2000: age-adjusted and age-specific rates by gender and cause. Wakai K, Nakai S, Kikuchi K, Iseki K, Miwa N, Masakane I, et al. Nephrol Dial Transplant 2004 19 2044 2052 10.1093/ndt/gfh317 15173379 (Pubitemid 39139636)
24. Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study. Schrier R, McFann K, Johnson A, Chapman A, Edelstein C, Brosnahan G, et al. J Am Soc Nephrol 2002 13 1733 1739 10.1097/01.ASN.0000018407.60002.B9 12089368 (Pubitemid 34700597)
25. Polycystic kidney disease at end-stage renal disease in the United States: patient characteristics and survival. Abbott KC, Agodoa LY, Clin Nephrol 2002 57 208 214 10.5414/CNP57208 11924752 (Pubitemid 34213659)
26. Peritoneal dialysis as the first-line renal replacement therapy in patients with autosomal dominant polycystic kidney disease. Li L, Szeto CC, Kwan BC, Chow KM, Leung CB, Kam-Tao LP, Am J Kidney Dis 2011 57 903 907 10.1053/j.ajkd.2011.01.019 21458901
27. Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. Gabow PA, Johnson AM, Kaehny WD, Kimberling WJ, Lezotte DC, Duley IT, et al. Kidney Int 1992 41 1311 1319 10.1038/ki.1992.195 1614046
28. Incident renal events and risk factors in autosomal dominant polycystic kidney disease: a population and family-based cohort followed for 22 years. Dicks E, Ravani P, Langman D, Davidson WS, Pei Y, Parfrey PS, Clin J Am Soc Nephrol 2006 1 710 717 10.2215/CJN.01581105 17699277
29. Autosomal dominant polycystic kidney disease in blacks: clinical course and effects of sickle-cell hemoglobin. Yium J, Gabow P, Johnson A, Kimberling W, Martinez-Maldonado M, J Am Soc Nephrol 1994 4 1670 1674 8011976
30. Diuretics versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic kidney disease. Ecder T, Edelstein CL, Fick-Brosnahan GM, Johnson AM, Chapman AB, Gabow PA, et al. Am J Nephrol 2001 21 98 103 10.1159/000046231 11359016 (Pubitemid 32453687)
31. Clinical characteristics and predictors of progression of chronic kidney disease in autosomal dominant polycystic kidney disease: a single center experience. Ozkok A, Akpinar TS, Tufan F, Kanitez NA, Uysal M, Guzel M, et al. Clin Exp Nephrol 2012 17 345 351 23085781
32. Emergent early markers of renal progression in autosomal-dominant polycystic kidney disease patients: implications for prevention and treatment. Helal I, Reed B, Schrier RW, Am J Nephrol 2012 36 162 167 10.1159/000341263 22846584
33. Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. Torres VE, Grantham JJ, Chapman AB, Mrug M, Bae KT, King BF Jr, et al. Clin J Am Soc Nephrol 2011 6 640 647 10.2215/CJN.03250410 21088290
34. ADPKD: Prototype of Cardiorenal Syndrome Type 4. Virzi GM, Corradi V, Panagiotou A, Gastaldon F, Cruz DN, de CM, et al. Int J Nephrol 2010 2011 490795 21234092
35. Polycystic kidney disease in patients on the renal transplant waiting list: trends in hematocrit and survival. Abbott KC, Agodoa LY, BMC Nephrol 2002 3 7 10.1186/1471-2369-3-7 12194700
36. Mineral and bone disorders and survival in hemodialysis patients with and without polycystic kidney disease. Lukowsky LR, Molnar MZ, Zaritsky JJ, Sim JJ, Mucsi I, Kovesdy CP, et al. Nephrol Dial Transplant 2012 27 2899 2907 10.1093/ndt/gfr747 22207323
37. Inflammation, Oxidative Stress, and Insulin Resistance in Polycystic Kidney Disease. Menon V, Rudym D, Chandra P, Miskulin D, Perrone R, Sarnak M, Clin J Am Soc Nephrol 2010 6 7 13 20829421
38. Polycystic kidney disease patients on renal replacement therapy: data from the Catalan Renal Registry. Torra R, Darnell A, Cleries M, Botey A, Revert L, Vela E, Contrib Nephrol 1995 115 177 181 8585911
39. Prevalence of cardiovascular events in patients with autosomal dominant polycystic kidney disease. Helal I, Reed B, Mettler P, Mc FK, Tkachenko O, Yan XD, et al. Am J Nephrol 2012 36 362 370 10.1159/000343281 23038404
40. Elevated circulating levels of interleukin-6 in patients with chronic renal failure. Herbelin A, Urena P, Nguyen AT, Zingraff J, scamps-Latscha B, Kidney Int 1991 39 954 960 10.1038/ki.1991.120 2067212
41. Analysis of baseline parameters in the HALT polycystic kidney disease trials. Torres VE, Chapman AB, Perrone RD, Bae KT, Abebe KZ, Bost JE, et al. Kidney Int 2012 81 577 585 10.1038/ki.2011.411 22205355
42. Favorable graft survival in renal transplant recipients with polycystic kidney disease. Johnston O, O'Kelly P, Donohue J, Walshe JJ, Little DM, Hickey D, et al. Ren Fail 2005 27 309 314 15957548 (Pubitemid 40770610)
43. Changes in causes of death and risk of cancer in Danish patients with autosomal dominant polycystic kidney disease and end-stage renal disease. Orskov B, Sorensen VR, Feldt-Rasmussen B, Strandgaard S, Nephrol Dial Transplant 2012 27 1607 1613 10.1093/ndt/gfr467 21873624
44. Causes of death in autosomal dominant polycystic kidney disease. Fick GM, Johnson AM, Hammond WS, Gabow PA, J Am Soc Nephrol 1995 5 2048 2056 7579053
45. Analysis of causes of mortality in patients with autosomal dominant polycystic kidney disease: a single center study. Rahman E, Niaz FA, Al-Suwaida A, Nahrir S, Bashir M, Rahman H, et al. Saudi J Kidney Dis Transpl 2009 20 806 810 19736478
46. Survival after starting renal replacement treatment in patients with autosomal dominant polycystic kidney disease: a single-centre 40-year study. Haynes R, Kheradmand F, Winearls CG, Nephron Clin Pract 2012 120 42 c47 10.1159/000334429 22205054
47. Autosomal dominant polycystic kidney disease in Toronto. Roscoe JM, Brissenden JE, Williams EA, Chery AL, Silverman M, Kidney Int 1993 44 1101 1108 10.1038/ki.1993.355 8264142 (Pubitemid 23316481)
48. Management of ESRD in patients with autosomal dominant polycystic kidney disease. Alam A, Perrone RD, Adv Chronic Kidney Dis 2010 17 164 172 10.1053/j.ackd.2009.12.006 20219619
49. Survival after end-stage renal disease in autosomal dominant polycystic kidney disease. Fourtounas C, Panteris V, Valis D, Am J Kidney Dis 2002 39 660 11877589 (Pubitemid 34194643)
50. Survival after end-stage renal disease in autosomal dominant polycystic kidney disease: contribution of extrarenal complications to mortality. Perrone RD, Ruthazer R, Terrin NC, Am J Kidney Dis 2001 38 777 784 10.1053/ajkd.2001. 27720 11576881 (Pubitemid 33666523)
51. Epidemiology and mortality in dialysis patients with and without polycystic kidney disease: a national study in Taiwan. Lee PW, Chien CC, Yang WC, Wang JJ, Lin CC, J Nephrol 2012 12 26 755 762